Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL-1 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04392505
What this trial is testing

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Who this might be right for
CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer Stage III+2 more
Oslo University Hospital 100
Early research (Phase 1)Ended earlyNCT03455556
What this trial is testing

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Who this might be right for
Mesothelin PositiveStage III Non-Small Cell Lung Cancer AJCC v7Stage IIIA Non-Small Cell Lung Cancer AJCC v7+2 more
Mayo Clinic 1
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Large-scale testing (Phase 3)Active Not RecruitingNCT05382286
What this trial is testing

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerPD-L1 Positive
Gilead Sciences 443
Early research (Phase 1)Study completedNCT03812549
What this trial is testing

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Who this might be right for
Stage IV NSCLC
Sichuan University 29
Not applicableUnknownNCT05964595
What this trial is testing

Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy

Who this might be right for
Head and Neck Squamous Cell CarcinomaMagnetic Resonance ImagingNeoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 136
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07819019
What this trial is testing

A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsGastric Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center 20
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Testing effectiveness (Phase 2)Active Not RecruitingNCT03620669
What this trial is testing

1st Line Durvalumab in PS 2 NSCLC Patients

Who this might be right for
NSCLC Stage IVNSCLC Stage IIIB
Swiss Cancer Institute 48
Testing effectiveness (Phase 2)Looking for participantsNCT07699939
What this trial is testing

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
National Cancer Center, Japan 136
Large-scale testing (Phase 3)Study completedNCT05064059
What this trial is testing

Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 441
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07459738
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Shanghai Henlius Biotech 60
Large-scale testing (Phase 3)Ended earlyNCT04740918
What this trial is testing

Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 96
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Not applicableUnknownNCT05228808
What this trial is testing

Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Adenocarcinoma
Sohag University 50
Testing effectiveness (Phase 2)UnknownNCT05151549
What this trial is testing

Carilizumab Combined With Concurrent Chemoradiotherapy

Who this might be right for
Cervical Cancer
Hunan Cancer Hospital 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Testing effectiveness (Phase 2)UnknownNCT05004974
What this trial is testing

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 20
Large-scale testing (Phase 3)UnknownNCT05042375
What this trial is testing

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 450
Testing effectiveness (Phase 2)Ended earlyNCT03430466
What this trial is testing

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 1
Next Page